Phase I Trial of Bortezomib in Combination with Rituximab-HyperCVAD/Methotrexate and Cytarabine for Untreated Mantle Cell Lymphoma

被引：0
|
作者：
Romaguera, Jorge [1 ]
Fayad, Luis [1 ]
McLaughlin, Peter [1 ]
Pro, Barbara [1 ]
Rodriguez, Maria Alma [1 ]
Wang, Michael [1 ]
Weaver, Pamela [1 ]
Hartig, Kimberly [1 ]
Kwak, Larry [1 ]
Feldman, Tatyana [2 ]
Smith, Judy [2 ]
Ford, Peggy [2 ]
Goldberg, Stuart [2 ]
Pecora, Andrew [2 ]
Goy, Andre [2 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Div Canc Med, Houston, TX 77030 USA
[2] Hackensack Univ, Med Ctr, Dept Lymphoma, Hackensack, NJ USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1049 / 1049
页数：1
相关论文
共 50 条
  • [31] Phase II study of bortezomib, cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma
    Shin, Junghoon
    Lee, Ji Yun
    Lee, Gyeong-Won
    Kim, Won Seog
    Park, Yong
    Do, Young Rok
    Kim, Dae Sik
    Kim, Ki Hwan
    Choi, Yoon Seok
    Byun, Ja Min
    Hong, Junshik
    Kim, Inho
    Yoon, Sung-Soo
    Koh, Youngil
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (06) : E54 - E57
  • [32] Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma
    Hess, Georg
    Wagner, Karola
    Keller, Ulrich
    La Rosee, Paul
    Atta, Johannes
    Huebel, Kai
    Lerchenmueller, Christian
    Schoendube, Daniel
    Witzens-Harig, Mathias
    Ruckes, Christian
    Medler, Christoph
    van Oordt, Christina
    Klapper, Wolfram
    Theobald, Matthias
    Dreyling, Martin
    HEMASPHERE, 2020, 4 (03):
  • [33] Phase II Trial of Bortezomib Plus Rituximab As Maintenance Therapy Post ASCT for Patients with Mantle Cell Lymphoma
    Chen, Robert W.
    Palmer, Joycelynne M.
    Popplewell, Leslie
    Alluin, Jessica
    Chomchan, Pritsana
    Nademanee, Auayporn P.
    Siddiqi, Tanya
    Tsai, Nicole
    Zuo, Fay
    Abary, Rosie
    Cai, Ji-lian
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry W.
    Holmberg, Leona
    BLOOD, 2017, 130
  • [34] Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
    Ruan, Jia
    Martin, Peter
    Furman, Richard R.
    Lee, Shing M.
    Cheung, Ken
    Vose, Julie M.
    LaCasce, Ann
    Morrison, Julia
    Elstrom, Rebecca
    Ely, Scott
    Chadburn, Amy
    Cesarman, Ethel
    Coleman, Morton
    Leonard, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (06) : 690 - 697
  • [35] Phase I/II trial of bortezomib plus CHOP-Rituximab in diffuse large B cell (DLBCL) and mantle cell lymphoma (MCL): Phase I results.
    Leonard, JP
    Furman, RR
    Cheung, YKK
    Feldman, EJ
    Cho, HJ
    Vose, JM
    Nichols, G
    Glynn, PW
    Joyce, MA
    Ketas, J
    Ruan, J
    Carew, J
    Niesvizky, R
    LaCasce, A
    Chadburn, A
    Cesarman, E
    Coleman, M
    BLOOD, 2005, 106 (11) : 147A - 147A
  • [36] A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
    Wang, Luhua
    Fayad, Luis
    Hagemeister, Fredrick B.
    Neelapu, Sattva
    Samaniego, Felipe
    McLaughlin, Peter
    Samuels, Barry
    Yi, Qing
    Pro, Barbara
    Fanale, Michelle
    Shah, Jatin
    Younes, Anas
    Bell, Neda
    Knight, Robert
    Zeldis, Jerome B.
    Cabanillas, Fernando
    Kwak, Larry
    Romaguera, Jorge
    BLOOD, 2009, 114 (22) : 1064 - 1065
  • [37] Potent single agent activity and tumor selectivity of bortezomib in mantle cell lymphoma: First impressions from a randomized phase II study of EPOCH-rituximab-bortezomib in untreated mantle cell lymphoma.
    Wiestner, A
    Dunleavy, K
    Rizzatti, EG
    Liu, H
    Marti, GE
    White, T
    Wilson, W
    BLOOD, 2005, 106 (11) : 266B - 266B
  • [38] The Results of a Phase I Study using Velcade (Bortezomib), Cladribine, and Rituximab (VCR) in treating Mantle Cell Lymphoma
    Pu, Jeffrey J.
    Ehmann, W. Christopher
    Liao, Jason
    Capper, Christine
    Levy, Michelle
    Claxton, David F.
    Rybka, Witold B.
    Hohl, Raymond J.
    Epner, Elliot M.
    BLOOD, 2016, 128 (22)
  • [39] A Phase II Trial of Bendamustine, Bortezomib, and Rituximab in Patients with Previously Untreated Low Grade Lymphoma
    Flinn, Ian W.
    Ervin, Thomas J.
    Boccia, Ralph V.
    Flora, Douglas B.
    Cuevas, J. Daniel
    Thompson, Dana S.
    Shipley, Dianna L.
    Berdeja, Jesus G.
    BLOOD, 2015, 126 (23)
  • [40] Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstrom's Macroglobulinemia
    Ghobrial, Irene M.
    Padmanabhan, Swaminathan
    Badros, Ashraf Z.
    Leduc, Renee
    Rourke, Meghan
    Chuma, Stacey
    Kunsman, Janet
    Warren, Diane
    Harris, Brianna
    Sam, Amy
    Anderson, Kenneth C.
    Richardson, Paul
    Treon, Steven
    Matous, Jeffrey
    BLOOD, 2009, 114 (22) : 1444 - 1444
12345